151 related articles for article (PubMed ID: 37910249)
1. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
Jeantin L; Shor N; Pallix-Guyot M; Roos-Weil D; Bellanger A; Le Garff-Tavernier M; Papeix C; Weiss N; Pourcher V
J Neurol; 2024 Feb; 271(2):729-732. PubMed ID: 37910249
[No Abstract] [Full Text] [Related]
2. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
3. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Barritt AW; Das E; Morley N; Seymour M; Saha R; Vera J; Vundavalli S; Dizdarevic S; Nicholas R; Berger JR; Fisniku LK
Mult Scler; 2023 Feb; 29(2):301-306. PubMed ID: 36451581
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
Motte J; Gold R
Mult Scler; 2023 Feb; 29(2):306-307. PubMed ID: 36451582
[No Abstract] [Full Text] [Related]
6. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
Warnke C; Adams O; Hartung HP; Gold R; Hemmer B; Hohlfeld R; Stangel M; Zipp F; Wiendl H; Kieseier BC
Nervenarzt; 2011 Oct; 82(10):1314-9. PubMed ID: 21656322
[No Abstract] [Full Text] [Related]
7. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
8. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
Ropper AH
N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
[No Abstract] [Full Text] [Related]
9. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
10. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab-associated progressive multifocal leukoencephalopathy.
Mancini N; Clementi M; Burioni R
N Engl J Med; 2012 Aug; 367(9):871-2; author reply 872. PubMed ID: 22931329
[No Abstract] [Full Text] [Related]
12. Natalizumab-associated progressive multifocal leukoencephalopathy.
Cervera C
N Engl J Med; 2012 Aug; 367(9):871; author reply 872. PubMed ID: 22931328
[No Abstract] [Full Text] [Related]
13. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
[TBL] [Abstract][Full Text] [Related]
14. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Giacomini PS; Rozenberg A; Metz I; Araujo D; Arbour N; Bar-Or A;
N Engl J Med; 2014 Jan; 370(5):486-8. PubMed ID: 24476450
[No Abstract] [Full Text] [Related]
17. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Ercan MB; Kocer B; Altiparmak T; Arslan I
Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
[No Abstract] [Full Text] [Related]
18. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
19. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
20. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
